What was the prior share repurchase activity under the old program?

As previously disclosed, in April 2026, Healthpeak repurchased 5.9 million common shares at a weighted average price of $16.81 per share for approximately $100 million. This activity occurred under the prior $500 million authorization, leaving approximately $400 million unused at the time of the July 2026 announcement of the new authorization.

How does the new authorization relate to Healthpeak's capital allocation priorities?

The new $500 million repurchase program is one component of Healthpeak's broader capital allocation strategy, which also includes debt reduction (the company repaid $650 million of senior notes and $375 million under its commercial paper program post-quarter), investment in outpatient medical and senior housing acquisitions, and a monthly dividend of $0.10167 per share ($1.22 annualized). Repurchases are opportunistic and executed at management's discretion.

What execution mechanism does Healthpeak use for repurchases?

The shares may be repurchased through various methods, including in the open market at Healthpeak's discretion, subject to market conditions, regulatory requirements, and other customary conditions. The disclosure does not specify whether a Rule 10b5-1 trading plan or 10b-18 safe harbor is employed, though standard open-market repurchases typically operate under 10b-18 guidelines.

Why did Healthpeak authorize a new program rather than amend the existing one?

The filing states the new authorization is 'replacing the existing $500 million authorization' without explaining the specific reason for replacement versus amendment. REITs typically reset authorizations periodically to ensure fresh Board approval and reinforce management's capital allocation flexibility.

What is Healthpeak's current share count and market capitalization context?

As of June 30, 2026, Healthpeak had 689,465,312 common shares outstanding. The second-quarter repurchase of 5.9 million shares represents approximately 0.85% of the outstanding share base. At the April execution price of $16.81 per share, the implied market cap was approximately $11.6 billion, making the $500 million authorization approximately 4.3% of market capitalization.

DOC 8-K Filed 2026-08-04 New authorization

Healthpeak authorizes new $500M share repurchase program

REIT replaces existing authorization following Brookfield joint venture capital raise and balance sheet strengthening

Authorization$500M

MechanismRule 10b-18 open-market purcha

What the filing says

Healthpeak Properties, Inc. (NYSE: DOC) announced in its second-quarter 2026 earnings release that its Board of Directors authorized a new $500 million share repurchase program in July 2026, replacing the existing $500 million authorization. The company disclosed that in April 2026, it had repurchased 5.9 million common shares at a weighted average share price of $16.81, representing approximately $100 million in repurchase activity under the prior authorization.

The new authorization permits repurchases through various methods, including open-market purchases at Healthpeak's discretion and subject to market conditions, regulatory requirements, and other customary conditions. The timing of this new authorization follows the company's execution of a major capital-generation transaction: in July 2026, Healthpeak closed a joint venture with Brookfield Asset Management, contributing an 86-property outpatient medical portfolio (5.6 million square feet) valued at approximately $2.1 billion and receiving proceeds of approximately $1.025 billion from the sale of Brookfield's 49% non-controlling equity interest.

Healthpeak has used its strengthened balance sheet—with $3.4 billion in liquidity as of August 3, 2026—to repay $650 million of senior notes at maturity and approximately $375 million under its commercial paper program, in addition to the share repurchase activity. The company continues to pursue capital allocation objectives including investments in outpatient medical and senior housing properties and dividend distributions to shareholders.

In July 2026, Healthpeak's Board of Directors authorized a new $500 million share repurchase program, replacing the existing $500 million authorization. The shares may be repurchased through various methods, including in the open market at Healthpeak's discretion and subject to market conditions, regulatory requirements, and other customary conditions. — HEALTHPEAK PROPERTIES, INC. 8-K filing · View on SEC EDGAR →

What this means

The new $500 million authorization represents a straightforward replacement of the prior authorization at the same dollar level, enabling Healthpeak to continue opportunistic repurchases as capital becomes available. The company repurchased approximately 5.9 million shares (less than 1% of outstanding shares of roughly 689 million) in April 2026 at $16.81 per share, reducing share count modestly. The timing follows a significant capital raise from the Brookfield joint venture, improving liquidity to approximately $3.4 billion. Repurchases remain discretionary and subject to market conditions, with no minimum or maximum annual targets disclosed. The authorization does not materially change the company's capital structure but provides flexibility as the company balances debt repayment, dividend maintenance at $1.22 annualized per share, and growth investments.

Frequently asked questions

What was the prior share repurchase activity under the old program?: As previously disclosed, in April 2026, Healthpeak repurchased 5.9 million common shares at a weighted average price of $16.81 per share for approximately $100 million. This activity occurred under the prior $500 million authorization, leaving approximately $400 million unused at the time of the July 2026 announcement of the new authorization.
How does the new authorization relate to Healthpeak's capital allocation priorities?: The new $500 million repurchase program is one component of Healthpeak's broader capital allocation strategy, which also includes debt reduction (the company repaid $650 million of senior notes and $375 million under its commercial paper program post-quarter), investment in outpatient medical and senior housing acquisitions, and a monthly dividend of $0.10167 per share ($1.22 annualized). Repurchases are opportunistic and executed at management's discretion.
What execution mechanism does Healthpeak use for repurchases?: The shares may be repurchased through various methods, including in the open market at Healthpeak's discretion, subject to market conditions, regulatory requirements, and other customary conditions. The disclosure does not specify whether a Rule 10b5-1 trading plan or 10b-18 safe harbor is employed, though standard open-market repurchases typically operate under 10b-18 guidelines.
Why did Healthpeak authorize a new program rather than amend the existing one?: The filing states the new authorization is 'replacing the existing $500 million authorization' without explaining the specific reason for replacement versus amendment. REITs typically reset authorizations periodically to ensure fresh Board approval and reinforce management's capital allocation flexibility.
What is Healthpeak's current share count and market capitalization context?: As of June 30, 2026, Healthpeak had 689,465,312 common shares outstanding. The second-quarter repurchase of 5.9 million shares represents approximately 0.85% of the outstanding share base. At the April execution price of $16.81 per share, the implied market cap was approximately $11.6 billion, making the $500 million authorization approximately 4.3% of market capitalization.
Does Healthpeak have any restrictions on the timing or size of repurchases?: The filing discloses no specific restrictions, limitations, or minimum/maximum annual targets. Repurchases are explicitly subject to market conditions, regulatory requirements, and other customary conditions, meaning Healthpeak can suspend or accelerate purchases based on its judgment and market circumstances.

authorization reit healthpeak rule-10b-18 capital-allocation healthcare-properties

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.